NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.500
+0.050 (3.45%)
At close: Feb 21, 2025, 4:00 PM
1.540
+0.040 (2.65%)
After-hours: Feb 21, 2025, 7:55 PM EST
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,337,824
Market Cap
23.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
NNVC News
- 4 days ago - NanoViricides, Inc. Has Filed its Quarterly Report - Accesswire
- 12 days ago - NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape - Accesswire
- 25 days ago - NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025 - Accesswire
- 27 days ago - NanoViricides Engages CRO for Phase II Clinical Trial - Accesswire
- 5 weeks ago - NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 - Accesswire
- 6 weeks ago - Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals - Accesswire
- 2 months ago - NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape - Accesswire
- 3 months ago - NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Accesswire